Psilocybin acts mainly through serotonin 5-HT2A signaling. Acute mechanisms are better characterized at perceptible research doses; the biological and clinical meaning of repeated very low doses remains uncertain.
Key facts
What the evidence supports
- 15-HT2A involvement is well supported for psychedelic effects.
- 2Neuroplasticity findings are strongest in preclinical and perceptible-dose research.
- 3Mechanistic plausibility is not proof of a health outcome.
Evidence quality
What can and cannot be concluded
Definitions, pharmacology, and documented community practices
Some basic mechanisms and commonly described practices are documented. That does not establish a consumer treatment effect.
Clinical outcomes from repeated low doses
Controlled microdosing studies remain limited, with mixed or null findings and meaningful expectation effects.
Psilocybin acts mainly through serotonin 5-HT2A signaling. Acute mechanisms are better characterized at perceptible research doses; the biological and clinical meaning of repeated very low doses remains uncertain.
Common questions
Answered without a universal protocol
What is the main evidence limitation?+
Most reported benefits come from observational or self-reported data; controlled microdosing findings remain limited and mixed.
Does this page provide personal instructions?+
No. It explains evidence and terminology, not an individualized dose, schedule, or medical decision.
Where is the deeper research?+
Use the exact iMicrodosing.org companion linked near the top of the page for citations and fuller context.
Product-format context
Product descriptions, laboratory documentation, fulfillment policies, and client support remain on iMicrodosing.com. Deeper research remains on iMicrodosing.org.
Educational information only. Not medical advice. 21+ only.